Hikma Pharmaceuticals PLC
Atvērts
SektorsVeselības aprūpe
1,473 -0.87
Pārskats
Akcijas cenas izmaiņa
24h
Min
1469
Max
1491
Ienākumi | 165M |
|---|---|
Pārdošana | 41M 1.7B |
P/E Sektora vidējais | 10.771 49.052 |
EPS | 1.07 |
Dividenžu ienesīgums | 5.74 |
Peļņas marža | 9.698 |
Darbinieki | 9,400 |
EBITDA | 152M 411M |
Rekomendācijas | Pirkt |
|---|---|
Prognoze 12 mēnešiem | +23.99% upside |
Dividenžu ienesīgums Sektora vidējais | 5.74% 2.36% |
|---|---|
Nākamie ieņēmumi | 2026. g. 6. aug. |
Nākamais Ex dividenžu datums | 2026. g. 13. aug. |
Tirgus kapitalizācija | -526M 3.1B |
|---|---|
Iepriekšējā atvēršanas cena | 1473.87 |
Iepriekšējā slēgšanas cena | 1473 |
Ziņu noskaņojums
By Acuity
43%
57%
118 / 342 Rangs Healthcare
Hikma Pharmaceuticals PLC Grafiks
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
Par Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
